Paul Edick biography
Paul Raymond Edick serves as Chairman of the Board, Chief Executive Officer of the Company. Prior to XERIS Pharmaceuticals, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From 2010 to 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics (Nasdaq: DRTX), a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata was acquired by Actavis plc in November 2014. Prior to Durata, Mr. Edick was Chief Executive Office of Ganic Pharmaceuticals, a Warburg Pincus investment search vehicle, from 2008 to 2010. Before Ganic, Mr. Edick was Chief Executive officer of MedPointe Healthcare, Inc., a US-based specialty pharmaceutical company, a position he assumed in 2006, having been President of Pharmaceutical Operations since 2002. Mr. Edick led the growth of the business, the development of a clinical stage portfolio, and the Company was subsequently sold to Meda, AB of Sweden in 2007. Mr. Edick currently serves on the Board of Directors for NewLink Genetics Inc. (Nasdaq: NLNK), Sucampo Pharmaceuticals (Nasdaq: SCMP), Neos Therapeutics (Nasdaq: NEOS), and PDL BioPharma (Nasdaq: PDLI). Mr. Edick has also previously served on a number of pharmaceutical and healthcare company boards including Circassia Pharmaceuticals Plc (London: CIR.L), Amerita Inc. and Informed Medical Communications. He was also Chairman of the Board of Life Cycle Pharma Ltd (fka Veloxis). Mr. Edick holds a Bachelor of Arts in Psychology from Hamilton College.
What is the salary of Paul Edick?
As the Chairman of the Board and Chief Executive Officer of Xeris Biopharma Inc, the total compensation of Paul Edick at Xeris Biopharma Inc is $4,307,640. There are no executives at Xeris Biopharma Inc getting paid more.
